+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment

Evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment

American Heart Journal 149(3): E21; Author Reply E23-4

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 048993826

Download citation: RISBibTeXText

PMID: 15864222

DOI: 10.1016/j.ahj.2004.11.026

Related references

Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. American Heart Journal 148(4): 582-589, 2004

The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial. American Heart Journal 157(1): 125-131, 2009

Evaluation of prophylactic dosages of Enoxaparin in non-surgical elderly patients with renal impairment. Bmc Pharmacology and Toxicology 20(1): 27, 2019

Dosing of Enoxaparin in Renal Impairment. P and T 42(4): 245-249, 2017

Enoxaparin 20 mg for thromboprophylaxis in severe renal impairment. Journal of International Medical Research 47(1): 225-234, 2019

Enoxaparin pharmacokinetics and pharmacodynamics in renal impairment. Journal of the American College of Cardiology 37(2 Suppl. A): 229A, 2001

Enoxaparin outcomes in patients with moderate renal impairment. Archives of Internal Medicine 172(22): 1713-1718, 2012

Dosage of enoxaparin among obese and renal impairment patients. Thrombosis Research 116(1): 41-50, 2005

Evaluation of Brain Pharmacokinetic and Neuropharmacodynamic Attributes of an Antiepileptic Drug, Lacosamide, in Hepatic and Renal Impairment: Preclinical Evidence. Acs Chemical Neuroscience 8(7): 1589-1597, 2017

Initiative to improve thromboprophylactic enoxaparin exposure in hospitalized patients with renal impairment. American Journal of Health-System Pharmacy 69(5): 390-396, 2012

Practical pharmacokinetic techniques for drug consultation and evaluation. IV: Gentamicin blood level versus time profiles of various dosage regimens recommended for renal impairment. American Journal of Hospital Pharmacy 32(3): 299-308, 1975

Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes. British Journal of Clinical Pharmacology 59(3): 281-290, 2005

Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thrombosis Research 105(3): 225-231, 2002

Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thrombosis Journal 12: 25, 2014

Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thrombosis and Haemostasis 97(4): 581-586, 2007